{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:28:31Z","timestamp":1783445311389,"version":"3.54.6"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2026-0095_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Although Graves\u2019 orbitopathy (GO) in childhood is generally considered milder than in adults, data regarding its clinical course and relationship with thyroid autoimmunity remain limited. This study aimed to evaluate the frequency and clinical characteristics of GO in pediatric patients with newly diagnosed hyperthyroidism and to assess short-term changes in ocular findings during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0095_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective observational study, 24 children with hyperthyroidism were enrolled. All ophthalmologic examinations were performed by the same ophthalmologist. Ocular findings were assessed according to the 2021 EUGOGO criteria, and disease activity was determined using the Clinical Activity Score (CAS). Thyroid function tests and autoantibodies, including anti-thyroid peroxidase antibody, thyrotropin receptor antibody, and thyroid-stimulating immunoglobulin, were evaluated at baseline and at 6\u00a0months. Associations between clinical, biochemical, and ophthalmologic parameters were analyzed statistically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0095_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age was 14.1\u00a0\u00b1\u00a03.4 years, and 75\u202f% of patients were female. At baseline, 83.3\u202f% had mild GO and 16.7\u202f% had moderate-to-severe disease. CAS values were &lt;3 at both time points in all patients, and no active orbitopathy was observed. Hertel measurements showed no significant changes during follow-up. Significant reductions in anti-thyroid peroxidase antibody, thyrotropin receptor antibody, and thyroid-stimulating immunoglobulin levels were observed at 6\u00a0months. Baseline Hertel values correlated positively with thyrotropin receptor antibody levels. Beta-blocker requirement decreased from 66.7\u202f% at baseline to none at 6\u00a0months. Only one patient (4.2\u202f%) showed transient progression in EUGOGO severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2026-0095_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In pediatric hyperthyroidism, GO is usually mild and inactive, with rare short-term clinical progression. Despite marked improvement in thyroid autoimmunity, ocular findings remained largely stable. These results support the generally benign course of childhood GO and emphasize the importance of detailed ophthalmologic assessment at diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2026-0095","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:46:29Z","timestamp":1779194789000},"page":"701-710","source":"Crossref","is-referenced-by-count":0,"title":["Clinical course of Graves\u2019 orbitopathy in children with newly diagnosed hyperthyroidism: a prospective observational study"],"prefix":"10.1515","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-3008","authenticated-orcid":false,"given":"Derya","family":"Tepe","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4804-3048","authenticated-orcid":false,"given":"Duygu","family":"Deligozoglu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-9230","authenticated-orcid":false,"given":"Ceyda","family":"Baskan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3597-9063","authenticated-orcid":false,"given":"Refika","family":"G\u00f6ren","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-0360","authenticated-orcid":false,"given":"P\u0131nar","family":"Kocaay","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2160-9838","authenticated-orcid":false,"given":"Fatih","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Y\u0131ld\u0131r\u0131m Beyaz\u0131t University , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-9128","authenticated-orcid":false,"given":"Mehmet","family":"Boyraz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Y\u0131ld\u0131r\u0131m Beyaz\u0131t University , Ankara , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026070716574687920_j_jpem-2026-0095_ref_001","doi-asserted-by":"crossref","unstructured":"Akkus, G, Ula\u015f, B, Binokay, H, Odabas, F, Soysal, RS, \u00d6zcan, A, et al.. Graves ophthalmopathy: a neglected comorbidity of Graves\u2019 disease; detailed investigation and management of sixty-eight patients in a tertiary healthcare center. BMC Endocr Disord 2025;25:1\u20138. https:\/\/doi.org\/10.1186\/S12902-025-01875-7.","DOI":"10.1186\/s12902-025-01875-7"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_002","doi-asserted-by":"crossref","unstructured":"Bahn, RS. Graves\u2019 ophthalmopathy. N\u00a0Engl J Med 2010;362:726\u201338. https:\/\/doi.org\/10.1056\/NEJMra0905750.","DOI":"10.1056\/NEJMra0905750"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_003","doi-asserted-by":"crossref","unstructured":"Bartalena, L. Childhood Graves\u2019 orbitopathy. In: Graves\u2019 orbitopathy. Basel: Karger; 2017:301\u20138 pp.","DOI":"10.1159\/000475968"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_004","doi-asserted-by":"crossref","unstructured":"Bartalena, L, Kahaly, GJ, Baldeschi, L, Dayan, CM, Eckstein, A, Marcocci, C, et al.. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 2021;185:G43\u201367. https:\/\/doi.org\/10.1530\/EJE-21-0479.","DOI":"10.1530\/EJE-21-0479"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_005","doi-asserted-by":"crossref","unstructured":"Chan, W, Wong, GWK, Fan, DSP, Cheng, ACK, Lam, DSC, Ng, JSK. Ophthalmopathy in childhood Graves\u2019 disease. Br J Ophthalmol 2002;86:740\u20132. https:\/\/doi.org\/10.1136\/bjo.86.7.740.","DOI":"10.1136\/bjo.86.7.740"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_006","doi-asserted-by":"crossref","unstructured":"Chua, MR, Tomlinson, LA, Binenbaum, G, Katowitz, WR. Pediatric thyroid eye disease: clinical characteristics and orbital decompression outcomes. Ophthalmic Plast Reconstr Surg 2018;34:S52\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000001137.","DOI":"10.1097\/IOP.0000000000001137"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_007","doi-asserted-by":"crossref","unstructured":"Eckstein, AK, Plicht, M, Lax, H, Neuh\u00e4user, M, Mann, K, Lederbogen, S, et al.. Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and predict severity and outcome. J\u00a0Clin Endocrinol Metab 2006;91:3464\u201370. https:\/\/doi.org\/10.1210\/jc.2005-2813.","DOI":"10.1210\/jc.2005-2813"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_008","doi-asserted-by":"crossref","unstructured":"Gerding, MN, van der Meer, JWC, Broenink, M, Bakker, O, Wiersinga, WM, Prummel, MF. Association of thyrotrophin receptor antibodies with clinical features of Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 2000;52:267\u201371. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00959.x.","DOI":"10.1046\/j.1365-2265.2000.00959.x"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_009","doi-asserted-by":"crossref","unstructured":"Hoang, TD, Stocker, DJ, Chou, EL, Burch, HB. 2022 update on clinical management of Graves\u2019 disease and thyroid eye disease. Endocrinol Metab Clin N Am 2022;51:287\u2013302. https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004.","DOI":"10.1016\/j.ecl.2021.12.004"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_010","doi-asserted-by":"crossref","unstructured":"Ionescu, IC, van Trotsenburg, PAS, Paridaens, D, Tanck, M, Mooij, CF, Cagienard, E, et al.. Pediatric Graves\u2019 orbitopathy: a multicentre study. Acta Ophthalmol 2022;100:e1340\u20138. https:\/\/doi.org\/10.1111\/aos.15084.","DOI":"10.1111\/aos.15084"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_011","doi-asserted-by":"crossref","unstructured":"Jarusaitiene, D, Verkauskiene, R, Jasinskas, V, Jankauskiene, J. Predictive factors of development of Graves\u2019 ophthalmopathy in juvenile Graves\u2019 disease. Internet J Endocrinol 2016;2016:8129497. https:\/\/doi.org\/10.1155\/2016\/8129497.","DOI":"10.1155\/2016\/8129497"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_012","doi-asserted-by":"crossref","unstructured":"Kahaly, GJ, Bartalena, L, Heged\u00fcs, L, Leenhardt, L, Poppe, K, Pearce, SH. 2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism. Eur Thyroid J. 2018;7:167\u201386. https:\/\/doi.org\/10.1159\/000490384.","DOI":"10.1159\/000490384"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_013","doi-asserted-by":"crossref","unstructured":"Krassas, GE, Gogakos, A. Thyroid-associated ophthalmopathy in juvenile Graves\u2019 disease: clinical, endocrine and therapeutic aspects. J\u00a0Pediatr Endocrinol Metab 2006;19:1193\u2013206. https:\/\/doi.org\/10.1515\/jpem.2006.19.10.1193.","DOI":"10.1515\/JPEM.2006.19.10.1193"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_014","doi-asserted-by":"crossref","unstructured":"Li, J, Austin, J, Douglas, RS, Nallasamy, S. Pediatric hyperthyroidism and thyroid eye disease management. J\u00a0AAPOS 2023;27:123\u20138. https:\/\/doi.org\/10.1016\/j.jaapos.2023.02.008.","DOI":"10.1016\/j.jaapos.2023.02.008"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_015","doi-asserted-by":"crossref","unstructured":"Marcocci, C, Marino, M. Treatment of mild, moderate-to-severe and very severe Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metabol 2012;26:325\u201337. https:\/\/doi.org\/10.1016\/j.beem.2011.11.005.","DOI":"10.1016\/j.beem.2011.11.005"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_016","doi-asserted-by":"crossref","unstructured":"Menconi, F, Marcocci, C, Marino, M. Diagnosis and classification of Graves\u2019 disease. Autoimmun Rev 2014;13:398\u2013402. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.013.","DOI":"10.1016\/j.autrev.2014.01.013"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_017","doi-asserted-by":"crossref","unstructured":"Ross, DS, Burch, HB, Cooper, DS, Greenlee, MC, Laurberg, P, Maia, AL, et al.. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421. https:\/\/doi.org\/10.1089\/thy.2016.0229.","DOI":"10.1089\/thy.2016.0229"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_018","doi-asserted-by":"crossref","unstructured":"San Miguel, I, Arenas, M, Carmona, R, Rutllan, J, Medina-Rivero, F, Lara, P. Review of the treatment of Graves\u2019 ophthalmopathy: the role of new radiation techniques. Saudi J Ophthalmol 2018;32:139\u201347. https:\/\/doi.org\/10.1016\/j.sjopt.2017.09.003.","DOI":"10.1016\/j.sjopt.2017.09.003"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_019","doi-asserted-by":"crossref","unstructured":"Stan, MN, Bahn, RS. Risk factors for development or deterioration of Graves\u2019 ophthalmopathy. Thyroid 2010;20:777\u201383. https:\/\/doi.org\/10.1089\/thy.2010.1634.","DOI":"10.1089\/thy.2010.1634"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_020","doi-asserted-by":"crossref","unstructured":"Stiebel-Kalish, H, Robenshtok, E, Hasanreisoglu, M, Ezrachi, D, Shimon, I, Leibovici, L. Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and meta-analysis. J\u00a0Clin Endocrinol Metab 2009;94:2708\u201316. https:\/\/doi.org\/10.1210\/jc.2009-0376.","DOI":"10.1210\/jc.2009-0376"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_021","doi-asserted-by":"crossref","unstructured":"Tanda, ML, Piantanida, E, Liparulo, L, Veronesi, G, Lai, A, Sassi, L, et al.. Prevalence and natural history of Graves\u2019 orbitopathy in newly diagnosed Graves\u2019 hyperthyroidism. J\u00a0Clin Endocrinol Metab 2013;98:1443\u20139. https:\/\/doi.org\/10.1210\/jc.2012-3873.","DOI":"10.1210\/jc.2012-3873"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_022","doi-asserted-by":"crossref","unstructured":"Vaidyanathan, P. Update on pediatric hyperthyroidism. Adv Pediatr 2022;69:219\u201329. https:\/\/doi.org\/10.1016\/j.yapd.2022.04.004.","DOI":"10.1016\/j.yapd.2022.04.004"},{"key":"2026070716574687920_j_jpem-2026-0095_ref_023","doi-asserted-by":"crossref","unstructured":"Wiersinga, WM. Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. Lancet Diabetes Endocrinol 2017;5:134\u201342. https:\/\/doi.org\/10.1016\/S2213-8587(16)30046-8.","DOI":"10.1016\/S2213-8587(16)30046-8"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0095\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:08:42Z","timestamp":1783444122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2026-0095\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,7,24]]}},"alternative-id":["10.1515\/jpem-2026-0095"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2026-0095","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}